Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Warfarin cohort

Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Warfarin cohort - JACRE-W

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015498

Enrollment

550

Registered

2014-10-22

Start date

2014-10-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation patients scheduled to undergo the catheter ablation procedure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-valvular atrial fibrillation patients scheduled to undergo the catheter ablation procedure and to have been receiving warfarin for at least 3 weeks at the time of admission for catheter ablation procedure

Exclusion criteria

Exclusion criteria: - Patients for whom catheter ablation for atrial fibrillation is contraindicated - Patients with a history of thromboembolism or myocardial infarction within 2 months prior to enrollment

Design outcomes

Primary

Measure	Time frame
Composite of thromboembolic events and major bleedings within 1 month since catheter ablation procedure - Thromboembolic events; transient ischemic attack, ischemic stroke, non-CNS systemic embolism - Major bleeding: pericardial effusion requiring a drainage procedure (cardiac tamponade),puncture hematoma requiring surgery, other bleeding episodes requiring blood transfusion, intracranial hemorrhage	—

Measure

Time frame

Composite of thromboembolic events and major bleedings within 1 month since catheter ablation procedure - Thromboembolic events; transient ischemic attack, ischemic stroke, non-CNS systemic embolism - Major bleeding: pericardial effusion requiring a drainage procedure (cardiac tamponade),puncture hematoma requiring surgery, other bleeding episodes requiring blood transfusion, intracranial hemorrhage

—

Secondary

Measure	Time frame
- Thromboembolism within 1 month since catheter ablation procedure - Major bleeding within 1 month since catheter ablation procedure - Non-major bleeding within 1 month since catheter ablation procedure	—

Countries

Japan

Contacts

Public ContactBell Medical Solutions Inc.

Bell Medical Solutions Inc. Clinical Research and Development Division

jimukyoku@medical-bs24.com0120-291-335

Outcome results